Tolerability and safety outcomes of first-line oral second-generation antipsychotics in patients with schizophrenia.
Kristen M WardCitrome LesliePublished in: Expert opinion on drug safety (2024)
Among antipsychotics, there are many differences in adverse reactions observed in clinical trials, such as variable likelihood to cause sedation vs insomnia, weight gain and abnormalities in glucose/lipid metabolism, hyperprolactinemia, potential for impact on the QT interval, and motoric adverse effects. Additional safety data that can help with medication selection include safety in pregnancy and lactation, and potential for drug-drug interactions. Ultimately, working with patients to personalize treatment by focusing on safety and individual tolerability considerations for various adverse effects can help in building a therapeutic alliance and improving patients' outcomes.
Keyphrases
- end stage renal disease
- clinical trial
- weight gain
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- body mass index
- healthcare
- electronic health record
- peritoneal dialysis
- adverse drug
- preterm birth
- blood pressure
- skeletal muscle
- study protocol
- birth weight
- big data
- climate change
- human health
- blood glucose
- patient reported
- physical activity
- deep learning
- placebo controlled
- replacement therapy
- gestational age